Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 22.71.
Forward PE Ratio (22.71) = Close Price ($34.26) / Consensus Forward EPS ($1.51)
FORWARD PE RATIO
22.71
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+14.03%
vs the sector median at left
Medline Inc.
Market Cap
$28.97B
Forward PE Ratio
22.71
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Medline Inc. (MDLN) | $28.97B | 22.71 |
| BioNTech SE (BNTX)vs › | $29.28B | N/A |
| Mettler-Toledo International Inc. (MTD)vs › | $28.19B | 29.48 |
| Labcorp Holdings Inc. (LH)vs › | $27.58B | 18.35 |
| Waters Corporation (WAT)vs › | $30.72B | 28.18 |
| Quest Diagnostics Incorporated (DGX)vs › | $26.97B | 21.84 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.61B | 36.30 |
| Biogen Inc. (BIIB)vs › | $32.03B | 17.40 |
| Incyte Corporation (INCY)vs › | $25.91B | 33.97 |
| Centene Corp. (CNC)vs › | $32.12B | 13.54 |
Trailing P/E
39.8
reported TTM EPS
Forward P/E
22.7
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.51 implies +75.6% EPS growth vs the reported trailing $0.86.
At today's $34.26 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.51 | $1.36 – $1.57 | 15 | 22.7x |
| 2027-12-31 | $1.57 | $1.48 – $1.67 | 15 | 21.8x |
| 2028-12-31 | $1.80 | $1.26 – $2.02 | 9 | 19.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
